Albuterol HFA
Asthma/COPD
CommercialActive
Key Facts
About Cipla
Founded in 1935, Cipla has established itself as a pioneering pharmaceutical company committed to improving global health outcomes through affordable medicines. The company operates across multiple therapeutic areas including respiratory, oncology, anti-retroviral, and complex generics, with a particular strength in inhalation products and biosimilars. Cipla's integrated business model spans from API manufacturing to finished formulations, with a growing focus on digital health solutions and specialty products for developed markets.
View full company profileOther Asthma/COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Symbicort | AstraZeneca | Approved |
| ProAir (albuterol) | Teva Pharmaceutical Industries | Commercial |
| Generic ProAir (Albuterol HFA) | Lupin Limited | Approved |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | Phase 3 |
| Generic Symbicort | Lupin Limited | Development |
| Generic Advair Equivalent | Cipla | Phase 3 |
| GRC 54276 | Glenmark Pharmaceuticals | Phase 2 |